Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the ...

The strategy has been great for Big Pharma’s bottom line—and for countries such as Ireland, too. But as President Trump’s ...

Thirdly, my system should determine the "golden mean" between financial risks and investment theses ... conduct a comparative analysis of those Johnson & Johnson and Pfizer medications that ...

Pfizer is currently a high-yield quality stock trading at reasonable valuations, indicating a margin of safety that surely curtails investment risks. With the stock market subject to bouts of ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

Click here and access our complete analysis report ... investor Starboard, Pfizer has remained resilient. Its strategic alliances in the oncology space and continued investment in pipeline ...

Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today.

China reassured foreign corporate leaders of its business prospects as Vice Premier He Lifeng met Apple and other major ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million in cash and a $350 million equity investment – with another $1.4 ...